-+ 0.00%
-+ 0.00%
-+ 0.00%

Sensorion Gets Support from Data Monitoring Committee for Hearing Loss Gene Therapy Trial

MT Newswires·12/08/2025 02:14:12
Listen to the news
02:14 AM EST, 12/08/2025 (MT Newswires) -- Sensorion (ALSEN.PA) said Monday that an independent data monitoring committee supported the continuation of its gene therapy program to treat congenital deafness linked to mutations in the otoferlin gene. The audiogene phase 1/2 clinical trial of SENS-501 aims to evaluate the safety, tolerability, and efficacy of intra-cochlear administration of SENS-501 for the treatment of hearing loss in paediatric patients aged six months to 31 months. The committee on Dec. 4 reviewed the first part of the trial, which consists of two sequential dose-escalation cohorts. The French biotechnology company plans to release the upcoming six-month efficacy data in the first quarter of 2026.